Human Longevity Stock
Human Longevity is on a mission to discover and harness the technological and biological unlocks that amplify span of life, health, and high-performance. HLI’s mission is to identify the therapeutically targetable mechanisms responsible for age-related human biological decline and to apply this intelligence to develop innovative solutions to interrupt or block those processes, meaningfully extending the human lifespan.
Sign up for SecondMarket™ to view the market and buy or sell Human Longevity Stock
Buy + SellHuman Longevity Funding
Sign up to gain insights into Human Longevity funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the Data| Date | Financing Round | Amount | Price per share* | Valuation* |
|---|---|---|---|---|
| Aug 21, 2024 | Series B | 21.50M | ||
| Apr 25, 2023 | Series B | 10.50M | ||
| Jun 18, 2019 | Series A | 20.06M | ||
| Feb 16, 2017 | Series B | 203.33M | ||
| Mar 26, 2015 | Series B | 319.50M | ||
| Mar 20, 2014 | Series A | 80.00M |
See Human Longevity Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Human Longevity Stock Valuation + Share Prices
View real-time Tape D™ data on Human Longevity stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get Started
Human Longevity Management Team
President, Chief Innovation Officer
David Karow
Director
Brett Blundy
Director
Wei-Wu He
Co-Founder, Director
Peter Diamandis
Chief Privacy Officer
Mert Gambito
Director
Alan B. Colowick
Director
Robert Duggan
Director
Robert Hariri
Director
Maky Zanganeh
Director
KT Lim
Chief Medical Officer
Julie Chen
Co-Founder
J. Craig Venter
Human Longevity Major Investors
Faridan Ventures
Illumina
GE Ventures (General Electric Company)
BB Retail Capital
Draper Fisher Jurvetson
Emerging Technology Partners LLC
Celgene Corp
Genting Berhad
OS Fund
TVM Capital Healthcare
Panacea Venture
Emerging Technology Partners
